The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The CRISPR/Cas adaptive immune system provides resistance against phages and plasmids in Archaea and Bacteria. CRISPR loci integrate short DNA sequences from invading genetic elements that provide small RNA-mediated interference in subsequent exposure to matching nucleic acids. In Streptococcus thermophilus, it was previously shown that the CRISPR1/Cas system can provide adaptive immunity against phages and plasmids by integrating novel spacers following exposure to these foreign genetic elements that subsequently direct the specific cleavage of invasive homologous DNA sequences. Here, we show that the S. thermophilus CRISPR3/Cas system can be transferred into Escherichia coli and provide heterologous protection against plasmid transformation and phage infection. We show that interference is sequence-specific, and that mutations in the vicinity or within the proto-spacer adjacent motif (PAM) allow plasmids to escape CRISPR-encoded immunity. We also establish that cas9 is the sole cas gene necessary for CRISPR-encoded interference. Furthermore, mutation analysis revealed that interference relies on the Cas9 McrA/HNH- and RuvC/RNaseH-motifs. Altogether, our results show that active CRISPR/Cas systems can be transferred across distant genera and provide heterologous interference against invasive nucleic acids. This can be leveraged to develop strains more robust against phage attack, and safer organisms less likely to uptake and disseminate plasmid-encoded undesirable genetic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular cloning: A laboratory manual
Deininger, P. (1990) · Analytical Biochemistry · doi:10.1016/0003-2697(90)90595-z · Cited by 84,682
Hall, T. A. (1999) · Nucleic Acids Symposium Series · doi:10.14601/phytopathol_mediterr-14998u1.29 · Cited by 38,297
Yanisch-Perron, C., Vieira, J., & Messing, J. (1985) · Gene · doi:10.1016/0378-1119(85)90120-9 · Cited by 15,041
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Self-citationConstruction and characterization of new cloning vehicles. II. A multipurpose cloning system. 1977.
Bolívar, F. G., Rl, R., Pj, G., Betlach, M. C., Hl, H., Boyer, H. W., Crosa, J. H., & Falkow, S. (1992) · PubMed · Cited by 4,672
Chang, A. C., & Cohen, S. N. (1978) · Journal of Bacteriology · doi:10.1128/jb.134.3.1141-1156.1978 · Cited by 4,243
Construction and characterization of new cloning vehicle. II. A multipurpose cloning system
Bolivar, F., Rodriguez, R. L., Greene, P. J., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, J. H., & Falkow, S. (1977) · Gene · doi:10.1016/0378-1119(77)90000-2 · Cited by 3,858
Construction and characterization of new cloning vehicles. II. A multipurpose cloning system.
Bolivar, F., Rodriguez, R. L., Greene, P. J., Betlach, M. C., Heyneker, H. L., Boyer, H. W., Crosa, J. H., & Falkow, S. (1977) · PubMed · Cited by 2,750
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
Self-citation
Cited by
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
“By cleaving genomic sequences targeted by RNA sequences (4-6), such a system could greatly enhance the ease of genome engineering.”
BackgroundThe new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
CRISPR-Cas systems for editing, regulating and targeting genomes
Sander, J. D., & Joung, J. K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2842 · Cited by 3,153
Gasiunas, G., Barrangou, R., Horvath, P., & Siksnys, V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208507109 · Cited by 2,769
Self-citationIn vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
An updated evolutionary classification of CRISPR–Cas systems
Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., Saunders, S. J., Barrangou, R., Brouns, S. J. J., Charpentier, E., Haft, D. H., et al. (2015) · Nature Reviews Microbiology · doi:10.1038/nrmicro3569 · Cited by 2,480
Self-citationRNA-guided editing of bacterial genomes using CRISPR-Cas systems
Jiang, W., Bikard, D., Cox, D., Zhang, F., & Marraffini, L. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2508 · Cited by 2,429
C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector
Abudayyeh, O. O., Gootenberg, J. S., Konermann, S., Joung, J., Slaymaker, I. M., Cox, D. B. T., Shmakov, S., Makarova, K. S., Semenova, E., Minakhin, L., et al. (2016) · Science · doi:10.1126/science.aaf5573 · Cited by 2,336
Crystal structure of Cas9 in complex with guide RNA and target DNA
Nishimasu, H., Ran, F. A., Hsu, P. D., Konermann, S., Shehata, S. I., Dohmae, N., Ishitani, R., Zhang, F., & Nureki, O. (2014) · Cell · doi:10.1016/j.cell.2014.02.001 · Cited by 2,306
“Biochemical analyses at the domain levels have enabled site-specific engineering to convert the native Cas9 into a DNA nicking enzyme (Gasiunas et al., 2012; Jinek et al., 2012; Sapranauskas et al., 2011) that facilitates homology-directed repair in eukaryotic cells (Cong et al.”
BackgroundInfluentialRNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
“…Cas5 or Csn1) (Barrangou et al., 2007; Bolotin et al., 2005; Deltcheva et al., 2011; Garneau et al., 2010; Gasiunas et al., 2012; Jinek et al., 2012; Sapranauskas et al., 2011) has been harnessed to facilitate facile genetic ma- nipulations in a variety of cell types and organisms (reviewed…”
BackgroundInfluentialRNA-guided genetic silencing systems in bacteria and archaea
Wiedenheft, B., Sternberg, S. H., & Doudna, J. A. (2012) · Nature · doi:10.1038/nature10886 · Cited by 1,851
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Highly efficient Cas9-mediated transcriptional programming
Chavez, A., Scheiman, J., Vora, S., Pruitt, B. W., Tuttle, M., P R Iyer, E., Lin, S., Kiani, S., Guzman, C. D., Wiegand, D. J., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3312 · Cited by 1,622
Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation
Doench, J. G., Hartenian, E., Graham, D. B., Tothova, Z., Hegde, M., Smith, I., Sullender, M., Ebert, B. L., Xavier, R. J., & Root, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.3026 · Cited by 1,617
The CRISPR tool kit for genome editing and beyond
Adli, M. (2018) · Nature Communications · doi:10.1038/s41467-018-04252-2 · Cited by 1,545
Pattanayak, V., Lin, S., Guilinger, J. P., Ma, E., Doudna, J. A., & Liu, D. R. (2013) · Nature Biotechnology · doi:10.1038/nbt.2673 · Cited by 1,487
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease
Anders, C., Niewoehner, O., Duerst, A., & Jinek, M. (2014) · Nature · doi:10.1038/nature13579 · Cited by 1,323
High-throughput functional genomics using CRISPR-Cas9
Shalem, O., Sanjana, N. E., & Zhang, F. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3899 · Cited by 1,233
Structures of Cas9 endonucleases reveal RNA-mediated conformational activation
Jinek, M., Jiang, F., Taylor, D. W., Sternberg, S. H., Kaya, E., Ma, E., Anders, C., Hauer, M., Zhou, K., Lin, S., et al. (2014) · Science · doi:10.1126/science.1247997 · Cited by 1,230
CRISPR interference (CRISPRi) for sequence-specific control of gene expression
Larson, M. H., Gilbert, L. A., Wang, X., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013) · Nature Protocols · doi:10.1038/nprot.2013.132 · Cited by 1,212
Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems
Shmakov, S., Abudayyeh, O. O., Makarova, K. S., Wolf, Y. I., Gootenberg, J. S., Semenova, E., Minakhin, L., Joung, J., Konermann, S., Severinov, K., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.008 · Cited by 1,209
A guide to genome engineering with programmable nucleases
Kim, H., & Kim, J.-S. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3686 · Cited by 1,163
The Biology of CRISPR-Cas: Backward and Forward
Hille, F., Richter, H., Wong, S. P., Bratovič, M., Ressel, S., & Charpentier, E. (2018) · Cell · doi:10.1016/j.cell.2017.11.032 · Cited by 1,039
Diversity and evolution of class 2 CRISPR–Cas systems
Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., et al. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.184 · Cited by 1,029
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation
Bhaya, D., Davison, M., & Barrangou, R. (2011) · Annual Review of Genetics · doi:10.1146/annurev-genet-110410-132430 · Cited by 914
Self-citationBeyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation
Dominguez, A. A., Lim, W. A., & Qi, L. S. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.2 · Cited by 832
Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.038 · Cited by 862
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Barrangou, R., & Marraffini, L. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.03.011 · Cited by 832
Self-citationCRISPR-Cas immunity in prokaryotes
Marraffini, L. A. (2015) · Nature · doi:10.1038/nature15386 · Cited by 829
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Revenge of the phages: defeating bacterial defences
Samson, J. E., Magadán, A. H., Sabri, M., & Moineau, S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3096 · Cited by 698
CRISPR-mediated adaptive immune systems in bacteria and archaea
Sorek, R., Lawrence, C. M., & Wiedenheft, B. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-072911-172315 · Cited by 668
Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis
Hou, Z., Zhang, Y., Propson, N. E., Howden, S. E., Chu, L.-F., Sontheimer, E. J., & Thomson, J. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313587110 · Cited by 681
“The type II crRNAmaturation pathway was originally characterized in strains of Streptococcus pyogenes (32) and Streptococcus thermophilus (35, 36), and RNase III-catalyzed pre-crRNA processing is essential for interference in both native systems.”
BackgroundLin, Y., Cradick, T. J., Brown, M. T., Deshmukh, H., Ranjan, P., Sarode, N., Wile, B. M., Vertino, P. M., Stewart, F. J., & Bao, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku402 · Cited by 634
“The lack of activity with PAM-proximal sgRNA bulges in R01 and low levels of activity with PAM-proximal sgRNA bulges in R-30 are consistent with the reduced mismatch tolerance in the ‘seed sequence’ reported in previous studies (9,11,33).”
Advances in the delivery of RNA therapeutics: from concept to clinical reality
Kaczmarek, J. C., Kowalski, P. S., & Anderson, D. G. (2017) · Genome Medicine · doi:10.1186/s13073-017-0450-0 · Cited by 656
“The discovery of RNAguided DNA endonucleases such as Cas9 associated with CRISPR (clustered regularly interspaced short palindromic repeats), elements composing the prokaryotic adaptive immune system [121], equipped scientists with an easy-to-use and efficient platform to alter genomic information [122].”
BackgroundBroadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Topkar, V. V., Zheng, Z., & Joung, J. K. (2015) · Nature Biotechnology · doi:10.1038/nbt.3404 · Cited by 611
Past, present, and future of CRISPR genome editing technologies
Pacesa, M., Pelea, O., & Jinek, M. (2024) · Cell · doi:10.1016/j.cell.2024.01.042 · Cited by 609
“22,101,114,115 The discovery ofCas12ain2015markedapivotalexpansionbeyondCas9,offering an alternative nuclease with a distinct PAM requirement, guide RNA format, and DNA cleavage pattern.”
InfluentialCRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity
Cradick, T. J., Fine, E. J., Antico, C. J., & Bao, G. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt714 · Cited by 590
“This allowed a direct evaluation of the impact of the location and number of mismatches within the 12 bases nearest the PAM region, as well as those in the PAM region (that usually match the canonical NGG motif) (Table 1) on potential off-target activities (8,20).”
BackgroundIshino, Y., Krupovic, M., & Forterre, P. (2018) · Journal of Bacteriology · doi:10.1128/jb.00580-17 · Cited by 558
Comparison of Cas9 activators in multiple species
Chavez, A., Tuttle, M., Pruitt, B. W., Ewen-Campen, B., Chari, R., Ter-Ovanesyan, D., Haque, S. J., Cecchi, R. J., Kowal, E. J. K., Buchthal, J., et al. (2016) · Nature Methods · doi:10.1038/nmeth.3871 · Cited by 519
Generation of gene-modified mice via Cas9/RNA-mediated gene targeting
Shen, B., Zhang, J., Wu, H., Wang, J., Ma, K., Li, Z., Zhang, X., Zhang, P., & Huang, X. (2013) · Cell Research · doi:10.1038/cr.2013.46 · Cited by 511
Classification and evolution of type II CRISPR-Cas systems
Chylinski, K., Makarova, K. S., Charpentier, E., & Koonin, E. V. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku241 · Cited by 498
“Two readily identifiable, split nuclease domains of Cas9, namely HNH and RuvC-like nucleases, are required for target DNA cleavage (8,12,27,30,32,33).”
BackgroundLander, E. S. (2016) · Cell · doi:10.1016/j.cell.2015.12.041 · Cited by 488
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer
Wang, S.-W., Gao, C., Zheng, Y.-M., Yi, L., Lu, J.-C., Huang, X.-Y., Cai, J.-B., Zhang, P.-F., Cui, Y.-H., & Ke, A.-W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01518-8 · Cited by 478
CRISPR-Cas: biology, mechanisms and relevance
Hille, F., & Charpentier, E. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0496 · Cited by 442
Annotation and Classification of CRISPR-Cas Systems
Makarova, K. S., & Koonin, E. V. (2015) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2687-9_4 · Cited by 437
Programmable Removal of Bacterial Strains by Use of Genome-Targeting CRISPR-Cas Systems
Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2014) · mBio · doi:10.1128/mbio.00928-13 · Cited by 433
Self-citationCrystal Structure of Staphylococcus aureus Cas9
Nishimasu, H., Cong, L., Yan, W. X., Ran, F. A., Zetsche, B., Li, Y., Kurabayashi, A., Ishitani, R., Zhang, F., & Nureki, O. (2015) · Cell · doi:10.1016/j.cell.2015.08.007 · Cited by 433
Cas9 specifies functional viral targets during CRISPR–Cas adaptation
Heler, R., Samai, P., Modell, J. W., Weiner, C., Goldberg, G. W., Bikard, D., & Marraffini, L. A. (2015) · Nature · doi:10.1038/nature14245 · Cited by 419
CRISPR–Cas adaptation: insights into the mechanism of action
Amitai, G., & Sorek, R. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.14 · Cited by 417
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
Expanding the Biologist’s Toolkit with CRISPR-Cas9
Sternberg, S. H., & Doudna, J. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.02.032 · Cited by 404
CRISPR Interference Directs Strand Specific Spacer Acquisition
Swarts, D. C., Mosterd, C., van Passel, M. W. J., & Brouns, S. J. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035888 · Cited by 378
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems
Chylinski, K., Le Rhun, A., & Charpentier, E. (2013) · RNA Biology · doi:10.4161/rna.24321 · Cited by 353
Karvelis, T., Bigelyte, G., Young, J. K., Hou, Z., Zedaveinyte, R., Budre, K., Paulraj, S., Djukanovic, V., Gasior, S., Silanskas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa208 · Cited by 349
Self-citationMolecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR–Cas Systems
O'Connell, M. R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.06.029 · Cited by 346
Protospacer recognition motifs: Mixed identities and functional diversity
Shah, S. A., Erdmann, S., Mojica, F. J. M., & Garrett, R. A. (2013) · RNA Biology · doi:10.4161/rna.23764 · Cited by 341
Fonfara, I., Le Rhun, A., Chylinski, K., Makarova, K. S., Lécrivain, A.-L., Bzdrenga, J., Koonin, E. V., & Charpentier, E. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1074 · Cited by 328
Methodologies for Improving HDR Efficiency
Liu, M., Rehman, S., Tang, X., Gu, K., Fan, Q., Chen, D., & Ma, W. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00691 · Cited by 323
CRISPR-Cas9 system: A new-fangled dawn in gene editing
Gupta, D., Bhattacharjee, O., Mandal, D., Sen, M. K., Dey, D., Dasgupta, A., Kazi, T. A., Gupta, R., Sinharoy, S., Acharya, K., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116636 · Cited by 323
Genome‐scale engineering for systems and synthetic biology
Esvelt, K. M., & Wang, H. H. (2013) · Molecular Systems Biology · doi:10.1038/msb.2012.66 · Cited by 320
A decade of discovery: CRISPR functions and applications
Barrangou, R., & Horvath, P. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.92 · Cited by 319
Self-citationMethods for Optimizing CRISPR-Cas9 Genome Editing Specificity
Tycko, J., Myer, V. E., & Hsu, P. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.07.004 · Cited by 305
CRISPR technologies and the search for the PAM-free nuclease
Collias, D., & Beisel, C. L. (2021) · Nature Communications · doi:10.1038/s41467-020-20633-y · Cited by 304
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
Ramanan, V., Shlomai, A., Cox, D. B. T., Schwartz, R. E., Michailidis, E., Bhatta, A., Scott, D. A., Zhang, F., Rice, C. M., & Bhatia, S. N. (2015) · Scientific Reports · doi:10.1038/srep10833 · Cited by 304
Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity
Charpentier, E., Richter, H., van der Oost, J., & White, M. F. (2015) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuv023 · Cited by 289
Rational design of a split-Cas9 enzyme complex
Wright, A. V., Sternberg, S. H., Taylor, D. W., Staahl, B. T., Bardales, J. A., Kornfeld, J. E., & Doudna, J. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501698112 · Cited by 286
Processing-Independent CRISPR RNAs Limit Natural Transformation in Neisseria meningitidis
Zhang, Y., Heidrich, N., Ampattu, B. J., Gunderson, C. W., Seifert, H. S., Schoen, C., Vogel, J., & Sontheimer, E. J. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.001 · Cited by 284
TALEN and CRISPR/Cas Genome Editing Systems: Tools of Discovery
Nemudryi, A. A., Valetdinova, K. R., Medvedev, S. P., & Zakian, S. M. (2014) · Acta Naturae · doi:10.32607/20758251-2014-6-3-19-40 · Cited by 281
PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures
Gleditzsch, D., Pausch, P., Müller-Esparza, H., Özcan, A., Guo, X., Bange, G., & Randau, L. (2019) · RNA Biology · doi:10.1080/15476286.2018.1504546 · Cited by 280
Nidhi, S., Anand, U., Oleksak, P., Tripathi, P., Lal, J. A., Thomas, G., Kuca, K., & Tripathi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073327 · Cited by 276
Degenerate target sites mediate rapid primed CRISPR adaptation
Fineran, P. C., Gerritzen, M. J. H., Suárez-Diez, M., Künne, T., Boekhorst, J., van Hijum, S. A. F. T., Staals, R. H. J., & Brouns, S. J. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400071111 · Cited by 275
(Ph)ighting Phages: How Bacteria Resist Their Parasites
Rostøl, J. T., & Marraffini, L. (2019) · Cell Host & Microbe · doi:10.1016/j.chom.2019.01.009 · Cited by 270
Jiang, W., Zhao, X., Gabrieli, T., Lou, C., Ebenstein, Y., & Zhu, T. F. (2015) · Nature Communications · doi:10.1038/ncomms9101 · Cited by 267
A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing
Edraki, A., Mir, A., Ibraheim, R., Gainetdinov, I., Yoon, Y., Song, C.-Q., Cao, Y., Gallant, J., Xue, W., Rivera-Pérez, J. A., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.12.003 · Cited by 265
“In Type II systems, CRISPR RNA (crRNA) is bound to a transactivating crRNA (tracrRNA) and loaded onto a Cas9 protein that cleaves complementary nucleic acids (Garneau et al., 2010; Deltcheva et al., 2011; Sapranauskas et al., 2011; Gasiunas et al., 2012; Jinek et al., 2012).”
BackgroundStreptococcus thermophilus CRISPR-cas9 systems enable specific editing of the human genome
Müller, M., Lee, C. M., Gasiunas, G., Davis, T. H., Cradick, T. J., Siksnys, V., Bao, G., Cathomen, T., & Mussolino, C. (2016) · Molecular Therapy · doi:10.1038/mt.2015.218 · Cited by 254
Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9
Singh, D., Sternberg, S. H., Fei, J., Doudna, J. A., & Ha, T. (2016) · Nature Communications · doi:10.1038/ncomms12778 · Cited by 263
Guide RNA Functional Modules Direct Cas9 Activity and Orthogonality
Briner, A. E., Donohoue, P. D., Gomaa, A. A., Selle, K., Slorach, E. M., Nye, C. H., Haurwitz, R. E., Beisel, C. L., May, A. P., & Barrangou, R. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.09.019 · Cited by 261
Self-citationThe roles of CRISPR–Cas systems in adaptive immunity and beyond
Barrangou, R. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.12.008 · Cited by 259
Self-citationMemory of viral infections by CRISPR-Cas adaptive immune systems: Acquisition of new information
Fineran, P. C., & Charpentier, E. (2012) · Virology · doi:10.1016/j.virol.2012.10.003 · Cited by 259
Adaptation in CRISPR-Cas Systems
Sternberg, S. H., Richter, H., Charpentier, E., & Qimron, U. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.01.030 · Cited by 253
CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo
Chang, H., Yi, B., Ma, R., Zhang, X., Zhao, H., & Xi, Y. (2016) · Scientific Reports · doi:10.1038/srep22312 · Cited by 242
In vitro reconstitution of Cascade‐mediated CRISPR immunity in Streptococcus thermophilus
Sinkunas, T., Gasiunas, G., Waghmare, S. P., Dickman, M. J., Barrangou, R., Horvath, P., & Siksnys, V. (2013) · The EMBO Journal · doi:10.1038/emboj.2012.352 · Cited by 228
Self-citationRapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements
Karvelis, T., Gasiunas, G., Young, J., Bigelyte, G., Silanskas, A., Cigan, M., & Siksnys, V. (2015) · Genome Biology · doi:10.1186/s13059-015-0818-7 · Cited by 225
“requirement have been previously reported [6, 7, 10, 24], were examined.”
BackgroundInfluentialSelf-citationMolecular Mechanisms of CRISPR-Cas Immunity in Bacteria
Nussenzweig, P. M., & Marraffini, L. A. (2020) · Annual Review of Genetics · doi:10.1146/annurev-genet-022120-112523 · Cited by 214
Generating rats with conditional alleles using CRISPR/Cas9
Ma, Y., Zhang, X., Shen, B., Lu, Y., Chen, W., Ma, J., Bai, L., Huang, X., & Zhang, L. (2014) · Cell Research · doi:10.1038/cr.2013.157 · Cited by 195
Harnessing CRISPR–Cas systems for bacterial genome editing
Selle, K., & Barrangou, R. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.008 · Cited by 188
Self-citationBothmer, A., Phadke, T., Barrera, L. A., Margulies, C. M., Lee, C. S., Buquicchio, F., Moss, S., Abdulkerim, H. S., Selleck, W., Jayaram, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms13905 · Cited by 187
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 181
“To deactivate the nuclease activity of Cas9, alanine substitutions are introduced into the catalytic residues of the HNH and RuvC nuclease domains (Sapranauskas et al., 2011).”
BackgroundMethodInfluentialLo, T.-W., Pickle, C. S., Lin, S., Ralston, E. J., Gurling, M., Schartner, C. M., Bian, Q., Doudna, J. A., & Meyer, B. J. (2013) · Genetics · doi:10.1534/genetics.113.155382 · Cited by 178
“This research was supported in part by National Institutes of Health grant R0130702 to B.J.M. J.A.D. and B.J.M. are investigators of the Howard Hughes Medical Institute.”
BackgroundMethodInfluentialEfficient RNA/Cas9-mediated genome editing in Xenopus tropicalis
Guo, X., Zhang, T., Hu, Z., Zhang, Y., Shi, Z., Wang, Q., Cui, Y., Wang, F., Zhao, H., & Chen, Y. (2014) · Development · doi:10.1242/dev.099853 · Cited by 165
“tropicalis embryos are consistent with findings obtained in vitro and in bacteria and mammalian cell lines (Cong et al., 2013; Fu et al., 2013; Hsu et al., 2013; Jinek et al., 2012; Sapranauskas et al., 2011), further highlighting the importance of the 3′ protospacer sequence close to the PAM in designing gRNAs to eli…”
Background
Metadata
- Authors
- Sapranauskas, R., Gasiunas, G., Fremaux, C., Barrangou, R., Horvath, P., & Siksnys, V.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-08-03
- Volume
- 39
- Issue
- 21
- Pages
- 9275-9282
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- OpenAlex
- W2112295554
- Cited by
- 834
- References
- 40
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.